biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by KayakerBCon Dec 21, 2015 12:57pm

211 Views

Post# 24401642

RE:RE:HOLD THE FCK UP HERE FOR A MINUTE!!!!!!!!

To claim you "know" 2016 will be a prosperous new year is a stunning claim.

Not really. If they're confident of at least one licensing deal in 2016 it'll be a prosperous new year.

The science must already be validated by the client.

Possibly, but LSDs and Herceptin have been well advanced by BTI and either/both could result in deals in 2016. The advantage for LSDs and Herceptin is that LSD enzymes and Herceptin have been introduced into the CNS intrathecally, so much is known about their efficacy and safety in the brain.

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports